Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.

Blood (2025) 146 (Supplement 1): 684.

https://doi.org/10.1182/blood-2025-684

Published: 2025

Journal Articles

Elranatamab real-world step-up dosing patterns in relapsed-refractory multiple myeloma patients: Interim analysis Results of the AMbreLA study

Blood (2025) 146 (Supplement 1): 8151.

https://doi.org/10.1182/blood-2025-8151

Published: 2025

Journal Articles

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Blood (2025) 146 (Supplement 1): 5836.

https://doi.org/10.1182/blood-2025-5836

Published: 2025

Journal Articles

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

Blood (2025) 146 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2025-1797

Published: 2025

Journal Articles

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Blood (2025) 146 (Supplement 1): 744.

https://doi.org/10.1182/blood-2025-744

Published: 2025

Journal Articles

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Blood (2025) 146 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2025-2275

Published: 2025

Journal Articles

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Blood (2025) 146 (Supplement 1): 367.

https://doi.org/10.1182/blood-2025-367

Published: 2025

Journal Articles

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean-Marc Schiano, Mourad Tiab, Mohamad Mohty, Frederique Kuhnowski, Jean Fontan, Salomon Manier, Frederique Orsini-Piocelle, Laure Vincent, Sophie Rigaudeau, Xavier Leleu, Benjamin Hebraud, Laurent Flet, Jean-Valere Malfuson, Caroline Jacquet, Driss Chaoui, Nathalie Meuleman, Wajed Abarah, Lydia Montes, Riad Benramdane, Cecile Sonntag, Hacene Zerazhi, Alina Danu, Olivier Allangba, Mamoun Dib, Murielle Roussel, Sophie Cereja, Julien Depaus, Nicolas Branche, Helene Demarquette, Valentine Richez, Brieuc Cherel, Laurent Frenzel, Marie-Christiane Vekemans, Noemie Bigot, Herve Avet-Loiseau, Jill Corre, Philippe Moreau

Blood (2025) 146 (1): 52–61.

https://doi.org/10.1182/blood.2024026230

Published: 2025

Journal Articles

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Blood (2024) 144 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2024-193960

Published: 2024

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood (2024) 144 (Supplement 1): 584.

https://doi.org/10.1182/blood-2024-194593

Published: 2024

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Blood (2022) 140 (Supplement 1): 6631–6632.

https://doi.org/10.1182/blood-2022-159695

Published: 2022

Journal Articles

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Blood (2021) 138 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2021-147467

Published: 2021

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Romain Guieze, MD, Loic Ysebaert, MD PhD, Lysiane Molina, MD, Damien Roos-Weil, MDPhD, Anne-Sophie Michallet, MD PhD, Benedicte Hivert, MD, Julie Gay, MD, Alain Saad, MD, Luc Mathieu Fornecker, MD PhD, Julien Broséus, Valérie Rouille, Laëtitia Auvray, Alain Jacques Delmer, MD PhD, Pierre Feugier, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-136667

Published: 2020

Journal Articles

Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases

Pedro H Prata, MD, Cecile Bally, Thomas Prebet, MD PhD, Christian Recher, MD PhD, Geoffroy Venton, Xavier Thomas, MD, Emmanuel Raffoux, MD, Arnaud Pigneux, MD PhD, Thomas Cluzeau, MDPhD, Judith Desoutter, Julie Gay, Claude Preudhomme, PharmD, PhD, Pierre Fenaux, MD PhD, Lionel Ades, MD PhD

Blood (2017) 130 (Supplement 1): 1335.

https://doi.org/10.1182/blood.V130.Suppl_1.1335.1335

Published: 2017

Journal Articles

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

Blood (2014) 124 (21): 482.

https://doi.org/10.1182/blood.V124.21.482.482

Published: 2014

Journal Articles

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Miguel Hie, Julie Gay, Lionel Galicier, François Provôt, Claire Presne, Pascale Poullin, Guy Bonmarchand, Alain Wynckel, Ygal Benhamou, Philippe Vanhille, Aude Servais, Dominique Bordessoule, Jean-Philippe Coindre, Mohamed Hamidou, Jean-Paul Vernant, Agnès Veyradier, Paul Coppo, the French Thrombotic Microangiopathies Reference Centre

Blood (2014) 124 (2): 204–210.

https://doi.org/10.1182/blood-2014-01-550244

Published: 2014

Includes: Supplemental data

Journal Articles

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

Miguel HIE, MD, Julie Gay, MD, Lionel Galicier, MD, Francois Provot, Sandrine Malot, Pascale Poullin, MD, Guy Bonmarchand, MD, Alain Wynckel, MD, Ygal Benhamou, MD, Philippe Vanhille, Dominique Bordessoule, MD, PhD, Jean-Paul Vernant, Agnes Veyradier, MD PhD, Paul Coppo, MD PhD

Blood (2013) 122 (21): 448.

https://doi.org/10.1182/blood.V122.21.448.448

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.

Elranatamab real-world step-up dosing patterns in relapsed-refractory multiple myeloma patients: Interim analysis Results of the AMbreLA study

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only